Masaki Takeuchi1,2, Michael J Ombrello3, Yohei Kirino4, Burak Erer5, Ilknur Tugal-Tutkun5, Emire Seyahi6, Yilmaz Özyazgan6, Norman R Watts7, Ahmet Gül5, Daniel L Kastner1, Elaine F Remmers1. 1. Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, Maryland, USA. 2. Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 3. Translational Genetics and Genomics Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA. 4. Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 5. Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 6. Cerrahpaşa Faculty of Medicine, Istanbul University, Istanbul, Turkey. 7. Protein Expression Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland, USA.
Abstract
INTRODUCTION: Endoplasmic reticulum aminopeptidase-1 (ERAP1) protein is highly polymorphic with numerous missense amino acid variants. We sought to determine the naturally occurring ERAP1 protein allotypes and their contribution to Behçet's disease. METHODS: Genotypes of all reported missense ERAP1 gene variants with 1000 Genomes Project EUR superpopulation frequency >1% were determined in 1900 Behçet's disease cases and 1779 controls from Turkey. ERAP1 protein allotypes and their contributions to Behçet's disease risk were determined by haplotype identification and disease association analyses. RESULTS: One ERAP1 protein allotype with five non-ancestral amino acids was recessively associated with disease (p=3.13×10-6, OR 2.55, 95% CI 1.70 to 3.82). The ERAP1 association was absent in individuals who lacked HLA-B*51. Individuals who carry HLA-B*51 and who are also homozygous for the haplotype had an increased disease odds compared with those with neither risk factor (p=4.80×10-20, OR 10.96, 95% CI 5.91 to 20.32). DISCUSSION: The Behçet's disease-associated ERAP1 protein allotype was previously shown to have poor peptide trimming activity. Combined with its requirement for HLA-B*51, these data suggest that a hypoactive ERAP1 allotype contributes to Behçet's disease risk by altering the peptides available for binding to HLA-B*51. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
INTRODUCTION:Endoplasmic reticulum aminopeptidase-1 (ERAP1) protein is highly polymorphic with numerous missense amino acid variants. We sought to determine the naturally occurring ERAP1 protein allotypes and their contribution to Behçet's disease. METHODS: Genotypes of all reported missense ERAP1 gene variants with 1000 Genomes Project EUR superpopulation frequency >1% were determined in 1900 Behçet's disease cases and 1779 controls from Turkey. ERAP1 protein allotypes and their contributions to Behçet's disease risk were determined by haplotype identification and disease association analyses. RESULTS: One ERAP1 protein allotype with five non-ancestral amino acids was recessively associated with disease (p=3.13×10-6, OR 2.55, 95% CI 1.70 to 3.82). The ERAP1 association was absent in individuals who lacked HLA-B*51. Individuals who carry HLA-B*51 and who are also homozygous for the haplotype had an increased disease odds compared with those with neither risk factor (p=4.80×10-20, OR 10.96, 95% CI 5.91 to 20.32). DISCUSSION: The Behçet's disease-associated ERAP1 protein allotype was previously shown to have poor peptide trimming activity. Combined with its requirement for HLA-B*51, these data suggest that a hypoactive ERAP1 allotype contributes to Behçet's disease risk by altering the peptides available for binding to HLA-B*51. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Amir Kadi; Brigitte Izac; Roula Said-Nahal; Ariane Leboime; Liesbet Van Praet; Kurt de Vlam; Dirk Elewaut; Gilles Chiocchia; Maxime Breban Journal: Ann Rheum Dis Date: 2012-08-15 Impact factor: 19.103
Authors: Emma Reeves; Alexandra Colebatch-Bourn; Tim Elliott; Christopher J Edwards; Edward James Journal: Proc Natl Acad Sci U S A Date: 2014-11-24 Impact factor: 11.205
Authors: Pablo Guasp; Carlos Alvarez-Navarro; Patricia Gomez-Molina; Adrian Martín-Esteban; Miguel Marcilla; Eilon Barnea; Arie Admon; José A López de Castro Journal: Arthritis Rheumatol Date: 2016-02 Impact factor: 10.995
Authors: Xiaoming Jia; Buhm Han; Suna Onengut-Gumuscu; Wei-Min Chen; Patrick J Concannon; Stephen S Rich; Soumya Raychaudhuri; Paul I W de Bakker Journal: PLoS One Date: 2013-06-06 Impact factor: 3.240
Authors: Pablo Guasp; Elena Lorente; Adrian Martín-Esteban; Eilon Barnea; Paolo Romania; Doriana Fruci; JonasJ W Kuiper; Arie Admon; José A López de Castro Journal: Mol Cell Proteomics Date: 2019-05-15 Impact factor: 5.911
Authors: Amity R Roberts; Louise H Appleton; Adrian Cortes; Matteo Vecellio; Jonathan Lau; Laura Watts; Matthew A Brown; Paul Wordsworth Journal: Proc Natl Acad Sci U S A Date: 2017-01-03 Impact factor: 11.205
Authors: Pablo Guasp; Eilon Barnea; M Francisca González-Escribano; Anaïs Jiménez-Reinoso; José R Regueiro; Arie Admon; José A López de Castro Journal: J Biol Chem Date: 2017-04-26 Impact factor: 5.157
Authors: Alejandro Sanz-Bravo; Carlos Alvarez-Navarro; Adrian Martín-Esteban; Eilon Barnea; Arie Admon; José A López de Castro Journal: Mol Cell Proteomics Date: 2018-04-09 Impact factor: 5.911
Authors: Chrysoula Dimopoulou; Jens D Lundgren; Jon Sundal; Henrik Ullum; Pål Aukrust; Finn C Nielsen; Rasmus L Marvig Journal: J Hum Genet Date: 2019-12-23 Impact factor: 3.172